Negative side effects are a feature of PE, not a bug.
As in any enterprise when price and speed (returning capital to limited partners) are the priorities, sacrificing quality is taken as a given. The only question is how far they can push until the ramifications impact one of the other two legs of the value equation (price/quality/timing).
And PE fund managers will never shy away from finding out.
Negative side effects are a feature of PE, not a bug.
As in any enterprise when price and speed (returning capital to limited partners) are the priorities, sacrificing quality is taken as a given. The only question is how far they can push until the ramifications impact one of the other two legs of the value equation (price/quality/timing).
And PE fund managers will never shy away from finding out.
Profit first, patient health dead last (pun intended). I’m almost too afraid to ask just ust how big is this iceberg?